Previous 10 | Next 10 |
On Tuesday Oct 5, ANVS announced the results from their phase 2 dose-ranging study in Parkinson's Disease. Responding to the news, the stock declined by >13% to close at $26.35 from the previous close. I take a look at the data and share my thoughts here. For further deta...
Shares of Cassava Sciences (SAVA -6.2%) are down in afternoon trading after announcing this morning it was starting a phase 3 trial of simufilam for Alzheimer's disease. Shares traded up in premarket trading. Although shares are up more than 738% year-to-date, the stock has had a roller ...
Marine Petroleum Trust (NASDAQ:MARPS) +52%. U.S. Energy USEG +23% new assets to nearly quadruple production Annovis Bio (NYSE:ANVS) +16% announces positive phase 2 efficacy data for the treatment of parkinson's disease Team TISI +14% wins upstream mechanical insp...
Data Shows Statistically Significant Improvements in Speed and Motor Function in PD Patients Annovis Bio to Request Meeting with FDA on Next Steps in Clinical Development Investor Conference Call to be Hosted Tuesday, October 5 th , 2021, at 9:00 am ET Berwyn, Pennsylvania--(Newsf...
The following slide deck was published by Annovis Bio, Inc. in conjunction with this event. For further details see: Annovis Bio (ANVS) Investor Presentation - Slideshow
Dr. Maria Maccecchini will present a corporate update on Tuesday, September 28 at 11:20am ET Berwyn, Pennsylvania--(Newsfile Corp. - September 24, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's dise...
Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PR Newswire BERWYN, Pa. , Sept. 10, 2021 /PRNewswire/ -- Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addre...
Berwyn, Pennsylvania--(Newsfile Corp. - September 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) , a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS), today announced tha...
On Aug 31, ACIU reported mixed p2 Alzheimer's Disease (AD) trial data. While comparing ACIU and ANVS' AD trial data, some ANVS investors on Stocktwits forum seem unclear about ANVS' p2a data. I take a look at ANVS' latest presentation at the Biomarkers for Alzheimer's Disease Summ...
Radnor, Pennsylvania--(Newsfile Corp. - August 31, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed against Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis") on behalf of those who purchased or acquired Annov...
News, Short Squeeze, Breakout and More Instantly...
Annovis Bio (NYSE: ANVS) , a late-stage, drug-platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (“AD”) and Parkinson’s disease (“PD”), today announced the receipt of U.S. Patent No. 12,042,482. The patent ...
MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...
The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYS...